Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 163

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 163
---
 to Agreement and Plan of Merger]</div>

| 48 |

<div align='center'>Schedule A to Agreement and Plan of Merger</div>

At the effective time of the Merger (the “Effective Time”), each outstanding share of common stock of
SKNY, $0.0001 par value per share (“SKNY Common Stock”), will be converted into the right to receive such number of shares
of common stock of MIRA, $0.0001 par value per share (“MIRA Common Stock”) as is calculated in to the Exchange Ratio (the
“Closing”). The Exchange Ratio is calculated using the relative company valuations of each of MIRA and SKNY where the MIRA
share value is calculated on an as-issued basis and the SKNY share value is calculated on a fully diluted basis to include all issued
SKNY options and warrants. After giving effect to the Closing, the SKNY holders will hold not more than 50% of the shares of the combined
company.

| 49 |

Annex B

| SKNY Pharmaceuticals, Inc. | April 2025   |
| Valuation                  | Page 2 of 25 |

Dear Sir,

Upon your request, Moore Financial Consulting Ltd. (hereinafter: “MFC”), performed a valuation of SKNY Pharmaceuticals Inc. (“SKNY”, “the Company”).

Our study was performed based on the following:

| ● | SKNY’s       
 presentation |

| ● | Additional                                   
 Data received from the company’s management. |

| ● | Public      
 information |

This report was prepared based on information provided to us and from discussions held with the Company’s management. We did not verify the accuracy, reliability or completeness of the information provided and the procedures we used while performing the valuation do not constitute an audit or review made under any generally accepted auditing standards.

Our professional fees for this study were not subject to the results of this report.

Indemnification

It has been agreed by us, and Mira, that except for our willful misconduct, negligence or malice, we will not bear any responsibility vis-à-vis the Client or any third party, from any source and based on any cause, including tort, related to executing services according to this proposal, and the Client, and/or its representatives will not bring any claim and/or lawsuit against us, including via a third party notice, with regard to the services given by us to the Client.

It is agreed that any legal measures regarding this valuation must be taken no